A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
Status:
Completed
Trial end date:
2013-07-19
Target enrollment:
Participant gender:
Summary
The REVLIMID Registry will provide safety data from a large cohort of Taiwanese patients
treated with REVLIMID. In addition, the registry will provide efficacy data and outcomes in a
real-world setting (versus a clinical trial).